13 August, 2025
Invitation to participate
Through Retina Australia’s membership with Retina International, we are sharing with you a survey request from the European Medicines Agency (EMA).
The Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has started assessing the development plan for a new medicine for the treatment of retinitis pigmentosa (RP).
As part of their evaluation, the Committee would like to consult people living with RP to gain valuable insights through a survey.
To participate click here.
The European Medicines Agency (EMA)
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). It is responsible for the scientific evaluation, supervision and safety monitoring of medicines.
The Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has started assessing the development plan for a new medicine for the treatment of retinitis pigmentosa (RP). The PDCO is the EMA’s scientific committee responsible for activities on medicines for children and to support the development of such medicines in the European Union by providing scientific expertise and defining paediatric needs.
As part of their evaluation, the Committee would like to consult people living with RP to gain valuable insights on the questions in the survey.
Participation in the survey
This survey is for patients living with RP and patient representatives only.
It is not for industry representatives.
Your input will help inform the EMA’s work and ensure that patient perspectives are fully considered in the development of this medicine.
The survey is available in multiple languages; translations can be accessed directly within the survey form.
